Advertisement

Topics

Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia

13:56 EDT 20 Mar 2017 | Nature Publishing

The intrinsic resistance of BCR-ABL-expressing chronic myeloid leukemia stem cells to treatment with tyrosine-kinase inhibitors requires growth-factor signaling through the proteins c-Fos and DUSP1. Combined inhibition of BCR-ABL, c-Fos, and DUSP1 eradicated leukemia in vivo, pointing to a new therapeutic strategy for kinase-driven leukemias.

Original Article: Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia

NEXT ARTICLE

More From BioPortfolio on "Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia"

Quick Search
Advertisement
 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...